Capricor Therapeutics CAPR EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's EPS (diluted)?
- Capricor Therapeutics (CAPR) reported EPS (diluted) of -$0.59 in Q1 2026.
- How has Capricor Therapeutics's EPS (diluted) changed year-over-year?
- Capricor Therapeutics's EPS (diluted) decreased by 11.3% year-over-year, from -$0.53 to -$0.59.
- What is the long-term trend for Capricor Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Capricor Therapeutics's EPS (diluted) has grown at a 27.0% compound annual growth rate (CAGR), from -$0.87 to -$2.26.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.